Peptide Monographs

BPC-157 and TB-500 side by side

BPC-157 and TB-500 are both indexed under Tissue repair peptides. Every cell below carries the record it came from, and an axis with no retrieved value reads Unknown rather than being filled by inference.

Summary

The two are searched together more than any other pair in the tissue repair class. BPC-157 is a 15-residue gastric pentadecapeptide with a literature going back to 1994; TB-500 is a synthetic fragment of thymosin beta 4 whose literature is mostly doping control. One cited 2026 Joint Diseases and Related Surgery paper studies both in a rat Achilles tendon model.

[1, 2, 3, 4, 5]

Side by side

Curated comparison axes for BPC-157 and TB-500
AxisBPC-157TB-500
Reported mechanismThe retrieved literature frames the mechanism in terms of a relation to the nitric oxide system, and reports effects on growth hormone receptor expression in tendon fibroblasts. No single receptor target is established in the retrieved record set.[1, 10]A synthetic fragment of thymosin beta 4; the retrieved records characterise the material rather than report a mechanism of its own, so the actin-sequestering mechanism belongs to the parent peptide.[3, 4]
Molecular formulaC62H98N16O22[6]C38H68N10O14[12]
Molecular weight1419.5 g/mol[6]889 g/mol[12]
FDA application registerA query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[7]A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[13]

Where the two literatures diverge

The literatures differ in kind. The cited 2014 Current Pharmaceutical Design paper frames BPC-157 against the nitric oxide system, and its retrieved set is predominantly animal efficacy work. The cited 2012 Journal of Chromatography A and Drug Testing and Analysis papers characterise TB-500 as the acetylated 17-23 fragment of thymosin beta 4 for detection purposes, and no mechanism of its own is reported; the actin-sequestering mechanism belongs to the parent peptide. Neither returned an FDA application record.

[1, 2, 3, 4, 5]

Where this page sits

Full pages: BPC-157 and TB-500.

Shared class: Tissue repair peptides.

Other pairs in the same class

All side-by-side pages: index.

Sources

  1. Stable gastric pentadecapeptide BPC 157-NO-system relation. Curr Pharm Des (2014). pmid:23755725
  2. The beneficial effect of BPC 157, a 15 amino acid peptide BPC fragment, on gastric and duodenal lesions induced by restraint stress, cysteamine and 96% ethanol in rats. A comparative study with H2 receptor antagonists, dopamine promotors and gut peptides. Life Sci (1994). pmid:7904712
  3. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry. Journal of chromatography. A (2012). pmid:23084823
  4. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug testing and analysis (2012). pmid:22962027
  5. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint diseases and related surgery (2026). pmid:42542926
  6. PubChem Compound Summary for CID 9941957, Bpc-157. PubChem, National Library of Medicine (2026). pubchem:9941957
  7. Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:bpc-157
  8. The influence of a novel pentadecapeptide, BPC 157, on N(G)-nitro-L-arginine methylester and L-arginine effects on stomach mucosa integrity and blood pressure. Eur J Pharmacol (1997). pmid:9298922
  9. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985) (2011). pmid:21030672
  10. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules (2014). pmid:25415472
  11. Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression. Eur J Pharmacol (2007). pmid:17628536
  12. PubChem Compound Summary for CID 62707662, Unii-qhk6Z47gtg. PubChem, National Library of Medicine (2026). pubchem:62707662
  13. Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:tb-500
  14. Adsorption effects of the doping relevant peptides Insulin Lispro, Synachten, TB-500 and GHRP 5. Analytical biochemistry (2017). pmid:28887173
  15. TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and adulterated drugs. Drug testing and analysis (2023). pmid:36482504
  16. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences (2024). pmid:38382158
  17. Alkaline Phosphatase-Triggered Spatiotemporal Repair of Corneal Injury with TB500 Peptide Hydrogel. ACS applied materials & interfaces (2025). pmid:41359360

On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.

Related resources